摘要
[目的]观察鼻咽癌患者回输自体CIK细胞后EB病毒指标及免疫功能变化。[方法]收集鼻咽癌病例38例,其中放疗或/和化疗联合CIK组19例,放化疗组19例仅进行放疗或/和化疗。分别抽取放化疗后、CIK治疗后外周血作免疫指标及EB病毒指标检测。[结果]放化疗联合CIK组EB病毒指标较放化疗组明显降低,免疫功能指标较放化疗组提高。[结论 ]CIK生物治疗安全可靠,能有效降低EB病毒抗体滴度并改善患者的免疫功能。
[Purpose] To investigate the changes of antibodies of EB virus and the immunity after the CIK cells being transfused back to the patients with nasopharyngeal cancer(NPC). [Methods] There were 38 cases with NPC were enrolled,and 19 cases received chemoradiotherapy combined with immunotherapy with auto-cytokine induced killer cells,and the other 19 cases accepted radiochemotherapy only. The antibodies of EB virus and the immunity index in the peripheral blood of patients were measured and compared between the two groups. [Result] The antibodies of EB virus in combination group were all lower and the immunity indexes were all higher than those in radiochemotherapy group. [Conclusion] Adoptive immunotherapy with auto-cytokine induced killer cells is safe and effective in clinical and it is able to lower antibodies of EB virus,and improves the immunity of the patients.
出处
《中国肿瘤》
CAS
2015年第2期139-141,共3页
China Cancer
关键词
鼻咽癌
CIK细胞
生物治疗
免疫功能
nasopharyngeal carcinoma
auto-cytokine induced killer cells
biotherapy
immunity